Statins May Reduce Risk of Breast Cancer for Older Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

SAN FRANCISCO-Common cholesterol-lowering agents (statins) may be effective in the chemoprevention of breast cancer in older women, a new study shows. The data were presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO abstract 1647).

SAN FRANCISCO—Common cholesterol-lowering agents (statins) may be effective in the chemoprevention of breast cancer in older women, a new study shows. The data were presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO abstract 1647).

"It appears that older women who take cholesterol-lowering agents in the HMG-CoA reductase inhibitor family may also be protecting themselves against breast cancer," said Jane Cauley, DrPH, associate professor of epidemiology, University of Pittsburgh Graduate School of Public Health.

The study population included 7,791 white women (mean age, 77.1) who were participants in the Study of Osteoporotic Fractures, led by Dr. Cauley. Among these women, there were 293 current statin users. During an average of 5.4 years of follow-up, 191 women in the cohort developed breast cancer.

88% Reduction

The analysis showed that use of a statin reduced new breast cancer cases by 88%, after adjusting for age and body weight. The age-adjusted incidence rate of breast cancer was 2.1 per 1,000 person-years among statin users, compared with 4.7 per 1,000 person-years among nonusers. The rate of breast cancer among nonusers of statins was similar to the rate (4.6) observed in the United States for older white women (SEER data).

A total of 300 women (4%), similar to the number of statin users (293), reported the use of other lipid-lowering agents. No significant effect of other lipid-lowering agents on the incidence of breast cancer was seen in these women, however, Dr. Cauley said. 

Recent Videos
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content